Pfizer licenses three in‑vivo CAR‑T programs from Starna Therapeutics

Pfizer signed an exclusive licensing agreement with China‑based Starna Therapeutics for three pre‑IND in‑vivo CAR‑T programs targeting autoimmune diseases. The deal provides Pfizer with an upfront cash payment of $330 million and potential milestone payments of up to $2.3 billion, plus royalties on net sales. Pfizer will lead development, manufacture and commercialization outside Greater China and will use Starna’s in‑vivo CAR‑T technology platform for inflammation, immunology and oncology.

Pfizer says the agreement expands its pipeline in the emerging in‑vivo CAR‑T space and could help offset upcoming patent expirations (the company’s statement). The upfront cash and potential milestones represent a multi‑billion‑dollar opportunity that could add future revenue if the programs reach market.

  • 1Pfizer will pay Starna an upfront cash amount of $330 million.
  • 2Starna is eligible for up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products.
  • 3The agreement grants Pfizer exclusive rights outside Greater China to develop, manufacture and commercialize three pre‑IND in‑vivo CAR‑T programs for autoimmune diseases.
  • 4Pfizer will also obtain rights to use Starna’s in‑vivo CAR‑T technology in inflammation, immunology and oncology, with an option to expand rights into Greater China.
  • 5Michael Vincent, Pfizer’s Chief Inflammation and Immunology Officer, said the in‑vivo CAR‑T approach is an emerging and promising way to treat autoimmune diseases where current options fall short.

Sources